Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine

Journal of Molecular Biology

Volumn 285, Issue 5, 1999, Pages 2021-2034

  Sheikhnejad, Gholamreza ^f   Brank, Adam ^f   Christman, Judith K ^a   Goddard, Amanda ^b   Alvarez, Estela ^b   Ford Jr , Harry ^b   Marquez, Victor E ^b   Marasco, Canio J ^c   Sufrin, Janice R ^c   O'Gara, Margaret ^d   Cheng, Xiaodong ^e  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NONE

Author keywords

DNA methylation; ODN inhibitors of DNA C5 methyltransferase; Synthesis of the cyanoethyl phosphoramidite of 5,6 dihydro 5 aza 2' deoxycytidine; Transition state analogs; X ray crystallography

Indexed keywords

5 METHYLCYTOSINE; 5,6 DIHYDROAZACITIDINE; CYSTEINE; CYTOSINE; DNA (CYTOSINE 5) METHYLTRANSFERASE; FLUCYTOSINE; OLIGODEOXYRIBONUCLEOTIDE; S ADENOSYLHOMOCYSTEINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; COVALENT BOND; CRYSTALLOGRAPHY; DNA HELIX; DNA METHYLATION; ENZYME INHIBITION; MOUSE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL;

EID: 0033524951     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1998.2426     Document Type: Article

References (45)

1. Andrews P. R., Winkler D. A. Golles G., Woolridge K. R. H. The Design and Medicinal Applications of Transition-State Analogues in Drug Design: Fact or Fantasy. 1984;Academic Press, Inc. London.
2. Bagdassarian C. K., Schramm V. L., Schwartz S. D. Electrostatic potential analysis for enzy matic substrates, competitive inhibitors and transition state inhibitors. J. Am. Chem. Soc. 118:1996;8825-8836.
3. Baker D. J., Kan J. L., Smith S. S. Recognition of structural perturbations in DNA by human DNA(cytosine-5)methyltransferase. Gene. 74:1988;207-210.
4. Beisler J. A. Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine. J. Med. Chem. 21:1978;204-208.
5. Bhagwat A. S., Roberts R. J. Genetic analysis of the 5-azacytidine sensitivity of Escherichia coli K-12. J. Bacteriol. 169:1987;1537-1546.
6. Brunger A. T., Karplus M., Petsko G. A. Crystallographic refinement by simulated annealing: application to crambin. Acta Crystallog. sect. A. 45:1989;50-61.
7. Chen L., MacMillan A. M., Verdine G. L. Mutational separation of DNA binding from catalysis in a DNA cytosine methyltransferase. J. Am. Chem. Soc. 115:1993;5318-5319.
8. Christman J. K., Price P., Pedrinan L., Acs G. Correlation between hypomethylation of DNA and expression of globin genes in Friend erythroleukemia cells. Eur. J. Biochem. 81:1977;53-61.
9. Christman J. K., Mendelsohn N., Herzog D., Schneiderman N. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelaytic leukemia cells CHL-601. Cancer Res. 43:1983;763-769.
10. Christman J. K., Sheikhnejad G., Marasco C. J., Sufrin J. R. 5-Methyl-2′-deoxycytidine in single-stranded DNA can act in cis to signal de novo DNA methylation. Proc. Natl Acad. Sci. USA. 92:1995;7347-7351.
11. Cihak A. Biological effects of 5-azacytidine in eukaryotes. Oncology. 30:1974;405-422.
12. Constantinides P. G., Jones P. A., Gevers W. Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature. 267:1977;364-366.
13. Creusot F., Acs G., Christman J. K. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J. Biol. Chem. 257:1982;2041-2048.
14. Furey W. F., Swaminathan S. PHASES-95: a program package for processing and analyzing diffraction data from macromolecules. Methods Enzymol. 277:1997;590-620.
15. Goddard A. J., Marquez V. E. Synthesis of a phosphoramidite of 2′-deoxy-5,6-dihydro-5-azacytidine. Its potential application in the synthesis of DNA containing dihydro-5-aza- and 5-azacytosine bases. Tetrahedron Letters. 29:1988;1767-1770.
16. Goldberg J., Gryn J., Raza A., Bennett J., Browman G., Bryant J., Grunwald H. Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study. Am. J. Hematol. 43:1993;286-290.
17. Guckian K. M., Kool E. T. Highly precise shape mimicry by a difluorotoluene deoxynucleoside, a replication-competent substitute for thymidine. Angew. Chem. Int. Edit. 36:1997;2825-2828.
18. Jackson-Grusby L., Laird P. W., Magge S. N., Moeller B. J., Jaenisch R. Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc. Natl Acad. Sci. USA. 94:1997;4681-4685.
19. Jones P. A., Taylor S. M. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 20:1980;85-93.
20. Klimasauskas S., Roberts R. J. M. Hha I binds tightly to substrates containing mismatches at the target base. Nucl. Acids Res. 23:1995;1388-1395.
21. Klimasauskas S., Kumar S., Roberts R. J., Cheng X. Hha I methyltransferase flips its target base out of the DNA helix. Cell. 76:1994;357-369.
22. Klimasauskas S., Szyperski T., Serva S., Wuthrich K. Dynamic modes of the flipped-out cytosine during Hha I methyltransferase-DNA interactions in solution. EMBO J. 17:1998;317-324.
23. Kumar S., Cheng X., Pflugrath J. W., Roberts R. J. Purification, crystallization, and preliminary X-ray diffraction analysis of an M. Hha I-AdoMet complex. Biochemistry. 31:1992;8648-8653.
24. Kumar S., Horton J. R., Jones G. D., Walker R. T., Roberts R. J., Cheng X. DNA containing 4′-thio-2′-deoxycytidine inhibits methylation by Hha I methyltransferase. Nucl. Acids Res. 25:1997;2773-2783.
25. Lauster R., Trautner T. A., Noyer-Weidner M. Cytosine-specific type II DNA methyltransferases. A conserved enzyme core with variable target-recognizing domains. J. Mol. Biol. 206:1989;305-312.
26. Lin K. T., Momparler R. L., Rivard G. E. High-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine. J. Pharm. Sci. 70:1981;1228-1232.
27. Marasco C. J. Jr., Sufrin J. R. A convenient method for the direct incorporation of 5-fluoro-2′-deoxycytidine into oligodeoxynucleotides. J. Org. Chem. 57:1992;6363-6365.
28. McGregor D. B., Brown A. G., Cattanach P., Shepherd W., Riach C., Daston D. S., Caspary W. J. TFT and 6TG resistance of mouse lymphoma cells to analogs of azacytidine. Carcinogenesis. 10:1989;2003-2008.
29. Mi S., Roberts R. J. The DNA binding affinity of Hha I methylase is increased by a single amino acid substitution in the catalytic center. Nucl. Acids Res. 21:1993;2459-2464.
30. Moran S., Ren R. X., Kool E. T. A thymidine triphosphate shape analog lacking Watson-Crick pairing ability is replicated with high sequence selectivity. Proc. Natl Acad. Sci. USA. 94:1997;10506-10511.
31. O'Gara M., Klimasauskas S., Roberts R. J., Cheng X. Enzymatic C5-cytosine methylation of DNA: mechanistic implications of new crystal structures for Hha I methyltransferase-DNA-AdoHcy complexes. J. Mol. Biol. 261:1996a;634-645.
32. O'Gara M., Roberts R. J., Cheng X. A structural basis for the preferential binding of hemimethylated DNA by Hha I DNA methyltransferase. J. Mol. Biol. 263:1996b;597-606.
33. O'Gara M., Horton J., Roberts R. J., Cheng X. Structures of Hha I methyltransferase complexed with substrates containing mismatches at the target base. Nature Struct. Biol. 5:1998;872-877.
34. Pinto A., Zagonel V. 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia. 7:1993;51-60.
35. Posfai J., Bhagwat A. S., Posfai G., Roberts R. J. Predictive motifs derived from cytosine methyltransferases. Nucl. Acids Res. 17:1989;2421-2435.
36. Rochette J., Craig J. E., Thein S. L. Fetal hemoglobin levels in adults. Blood Rev. 8:1994;213-224.
37. Santi D. V., Norment A., Garrett C. E. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc. Natl Acad. Sci. USA. 81:1984;6993-6997.
38. Schramm V. L., Horenstein B. A., Kline P. C. Transition state analysis and inhibitor design for enzymatic reactions. J. Biol. Chem. 269:1994;18259-18262.
39. Shivapurkar N., Poirier L. A. Tissue levels of S-adenosylmethionine and S-adenosylhomocysteine in rats fed methyl-deficient, amino acid-defined diets for one to five weeks. Carcinogenesis. 4:1983;1051-1057.
40. Smith S. S., Lingeman R. G., Kaplan B. E. Recognition of foldback DNA by the human DNA (cytosine-5)-methyltransferase. Biochemistry. 31:1992;850-854.
41. Taylor S. M., Jones P. A. Mechanism of action of eukaryotic DNA methyltransferase. Use of 5-azacytosine-containing DNA. J. Mol. Biol. 162:1982;679-692.
42. Wainfan E., Dizik M., Stender M., Christman J. K. Rapid appearance of hypomethylated DNA in livers of rats fed cancer-promoting, methyl-deficient diets. Cancer Res. 49:1989;4094-4097.
43. Wu J. C., Santi D. V. Kinetic and catalytic mechanism of Hha I methyltransferase. J. Biol. Chem. 262:1987;4778-4786.
44. Wyszynski M. W., Gabbara S., Kubareva E. A., Romanova E. A., Oretskaya T. S., Gromova E. S., Shabarova Z. A., Bhagwat A. S. The cysteine conserved among DNA cytosine methylases is required for methyl transfer, but not for specific DNA binding. Nucl. Acids Res. 21:1993;295-301.
45. Yang A. S., Shen J. C., Zingg J. M., Mi S., Jones P. A. Hha I and Hpa II DNA methyltransferases bind DNA mismatches, methylate uracil and block DNA repair. Nucl. Acids Res. 23:1995;1380-1387.